



# Real World Testing Results

2023

*MedOne Systems, LLC  
2349 State Route 821 Building 7A, Marietta, OH 45750, USA  
info@medonesystems.com*



# General Information

<i>Developer Name:</i>	MedOne Systems, LLC
<i>Product Name:</i>	BOLT
<i>Version Number:</i>	v3.5
<i>Certified Health IT Product List (CHPL) Product Number:</i>	15.04.04.1901.BOLT.03.02.1.211122
<i>Developer Real World Testing Plan Page URL:</i>	<a href="https://www.medonesystems.com/bolt-certification">https://www.medonesystems.com/bolt-certification</a>

## Overview

Utilized in both the inpatient and ambulatory setting, BOLT is a software solution that enhances existing enterprise EHR, augmenting its clinical documentation functionality and promoting efficiency, effectiveness, and clinical staff satisfaction. This document describes MedOne Systems’ results of assessing real world usage metrics as defined by the 2023 Real World Testing Plan.

## Changes to Original Plan

<i>§ 170.315 (b)(2) Clinical Information Reconciliation and Incorporation</i>	
<i>Summary of Change</i>	The Real World Testing Plan for 2023 indicated that metrics would be obtained throughout the measurement period. The functionality of importing data for the reconciliation of problems, medications, and allergies was not used for the entire duration of the measurement period.
<i>Reason</i>	The customer elected not to adopt the functionality for the certification criteria during the measurement period.
<i>Impact</i>	As a result, measurement data was only collected for a portion of the period identified in the 2023 Real World Testing Plan.

<i>§ 170.315 (b)(3) Electronic Prescribing</i>	
<i>Summary of Change</i>	The Real World Testing Plan for 2023 indicated that metrics would be obtained throughout the measurement period. The functionality of receiving prescription messages from the pharmacy and medication history queries was not used by customers for the entire measurement period.
<i>Reason</i>	BOLT customers enabled the functionality for sending electronic prescription messages to the pharmacy for the entirety of 2023. The customer used the functionality to receive prescription information from the pharmacy in September of 2023. The functionality for querying a patient’s medication history was used in July 2023.
<i>Impact</i>	As a result, measurement data for sending of prescription messages and encounters where medication history was queried was only collected for a portion of the period identified in the 2023 Real World Testing Plan.

## Test Results

<i>§ 170.315 (b)(2) Clinical Information Reconciliation and Incorporation</i>	
Measurement/Metric	<ul style="list-style-type: none"> <li>• The number of CCDs correctly matched with patient demographics and imported for reconciliation</li> <li>• Number of Problems added/rejected</li> <li>• Number of Medications added/rejected</li> <li>• Number of Allergies added/rejected</li> </ul>
Relied Upon Software	Dynamic Health IT (DHIT) ConnectEHR
Care Settings	Real World Testing was completed in 2023 for both inpatient and ambulatory care settings.
Expected Outcome	BOLT customers can import and reconcile problems, medications, and allergies into the electronic health record.
Key Milestones	Data was collected and analyzed at the following time intervals: November 2023; January 2024
Challenges Encountered	Lack of utilization by the customer for the entire measurement period.


## Summary of Testing Methods and Key Findings

Clinical Information Reconciliation and Incorporation was tested in a real-world scenario. We specifically focused on customers who had used this functionality in their electronic health records. During the last quarter of 2023, one customer with a total of eighty-eight (88) ambulatory practice locations and three (3) hospitals was identified. These locations were chosen to participate in data collection and analysis for the real-world testing results. As part of this process, BOLT ran SQL scripts from the production environment to gather the necessary data for analysis, as outlined in our 2023 Real World Testing Plan.

## Final Outcome(s) & Measurements

BOLT, in conjunction with relied upon software, has enabled customers to receive CCDs into the electronic health record. Clinical users can validate patient identification, assess usefulness, and incorporate the information into the electronic health record for reconciliation as indicated. Customers are not required to implement this functionality and therefore it was expected that we would need to identify customers during the year that had functionality enabled. During the last quarter of 2023, we conducted customer identification, data collection, and analysis. The customer did not use the functionality for the entirety of the calendar year. As a result, the data collected was lower than our initial projections. However, data analysis demonstrates that the functionality for this certification criteria can be implemented in a real-world scenario.

MONTH (CY 2023)	OCT	NOV	DEC	TOTAL
The number of CCDs correctly matched with patient demographics and imported for reconciliation.	1,079	958	188	2,522
Number of Medications Reconciled	160	173	76	586
Number of Problems Reconciled	177	191	92	451
Number of Allergies Reconciled	201	219	105	513



## Test Results (Continued)

<i>§ 170.315 (b)(3) Electronic Prescribing</i>	
Measurement/Metric	<ul style="list-style-type: none"> <li>Count of prescription messages sent from BOLT using the NCPDP SCRIPT Standard Version 2017017, and successfully received by the pharmacy – NewRx, CancelRx, RxRenewalResponse, RxChangeResponse, NewRxResponseDenied. Outgoing Status, Verify and Error message acknowledgements will not be counted.</li> <li>Count of messages using the NCPDP SCRIPT Standard Version 2017071, containing prescription information received from pharmacies – RxFill, RxChangeRequest, RxRenewalRequest, CancelRxResponse, NewRxRequest. Incoming Status, Verify and Error message acknowledgements will not be counted.</li> <li>Count of encounters where a patient’s medication history was queried (RxHistoryRequest) and received (RxHistoryResponse) using the NCPDP SCRIPT Standard Version 2017071 and contained information about at least one medication.</li> </ul>
Relied Upon Software	Non-Applicable.
Care Settings	Real World Testing was completed in 2023 for both inpatient and ambulatory care settings.
Expected Outcome	Electronic communication between BOLT and pharmacies occurs regarding creating, cancelling, renewing, and changing prescriptions. The software also has the ability to query for and receive a patient’s medication history for review by a clinical user.
Key Milestones	Data was collected and analyzed at the following time intervals: January 2024
Challenges Encountered	Lack of utilization for the entire measurement period for receiving electronic messages from pharmacies and querying a patient’s medication history.


### Summary of Testing Methods and Key Findings

Electronic prescribing was tested in a real-world scenario. We specifically focused on customers who had enabled this functionality in their electronic health records. One customer with a total of eighty-eight (88) ambulatory practice locations and three (3) hospitals was identified. These locations were chosen to participate in data collection and analysis for the real-world testing results. As part of this process, BOLT ran SQL scripts from the production environment to gather the necessary data for analysis, as outlined in our 2023 Real World Testing Plan.


## Final Outcome(s) & Measurements

BOLT customers enabled the functionality for sending electronic prescription messages to the pharmacy for the entirety of 2023. The customer used the functionality to receive prescription information from the pharmacy beginning in September of 2023. The functionality for querying a patient’s medication history was used by the customer in July 2023. Since the customer elected not to have the functionality enabled for the entirety of the calendar year for all three metrics, the data collected was lower than our initial projections. However, data analysis demonstrates that the functionality for this certification criteria can be implemented in a real-world scenario.


MONTH (CY 2023)	JAN	FEB	MAR	APR	MAY	JUN
Rx Messages Sent	29,865	28,450	33,446	30,813	32,195	31,244
Rx Messages Received	0	0	0	0	0	0
Medication Hx Queried	0	0	0	0	0	0
MONTH (CY 2023)	JUL	AUG	SEP	OCT	NOV	DEC
Rx Messages Sent	28,817	33,282	38,464	63,337	70,099	66,288
Rx Messages Received	0	0	730	7,136	12,772	13,042
Medication Hx Queried	83	0	0	0	0	0



### Rx Messages Sent by Type CY 2023



### Rx Messages Received by Type CY 2023



# Test Results (Continued)

<i>§ 170.315 (c)(1) Record and Export</i>	
Measurement/Metric	Percentage of validated data elements captured/recorded in the EHR compared to data generation of QRDA files. Number of exported QRDA files.
Relied Upon Software	Dynamic Health IT (DHIT) CQM Solutions.
Care Settings	Real World Testing was completed in 2023 for the inpatient and ambulatory setting.
Expected Outcome	Customers will be able to track performance and report to CMS for compliance with quality programs.
Key Milestones	Data was collected and analyzed at the following time intervals: Quarterly in 2023 and January 2024
Challenges Encountered	Lack of utilization for QRDA I exports for hospital quality reporting.

## Summary of Testing Methods and Key Findings

Clinical Quality Measures were tested in a real-world scenario through auditing to confirm conformance to the recording and capturing of relevant data points for certified eCQMs. Manual auditing was applied using a systematic random sampling of patient data from QRDA files to evaluate compliance with §170.315 (c)(1). Data analysis revealed that customers exported approximately 195 QRDA files throughout each quarter of the calendar year for quality monitoring. These were QRDA III files as the data focus by the customer was for the ambulatory setting. QRDA I file exports were not used by the customer until January 2024 for a review of December 2023 data.

No QRDA I file exports were performed in 2023. However, customer outreach revealed that twenty-three QRDA III files were exported and successfully submitted to the Centers for Medicare and Medicaid Services (CMS) for the 2023 measurement period. No instances of non-conformity were identified during testing. These results demonstrate real-world interoperability and maintenance of the certification requirements as eCQM data was successfully recorded and exported.

## Final Outcome(s) & Measurements


Successful audits to determine compliance with the capturing of relevant data points for a sample of certified eCQMs. Data validation occurred throughout the calendar year and had a 100% validation rate for each sample population selected. Additionally, twenty-three QRDA III files were generated and submitted during the measurement period per customer outreach.

MONTH (CY 2023)	Q1	Q2	Q3	Q4
Validation of eCQM Data Capture	100%	100%	100%	100%
Number of QRDA Files Exported	195	195	195	218



# Attestation

These Real World Testing results are complete with all required elements, including measures that address all certification criteria and care settings. All information in this document is up to date and fully addresses metrics defined in the Real World Testing Plan.

<i>Authorized Representative Name</i>	Michelle Geese
<i>Authorized Representative Email</i>	mgeese@medonesystems.com
<i>Authorized Representative Phone</i>	(740) 242-7987
<i>Authorized Representative Signature</i>	
<i>Date</i>	2024-01-25